Category - Markets

Markets

Stifel cuts PhaseBio to hold on bentracimab ownership dispute

Stifel downgraded PhaseBio Pharmaceuticals (NASDAQ:PHAS) to “hold” from “buy” and slashed its price target to $1 from $15, citing an ownership dispute over PhaseBio’s bentracimab, a potential ticagrelor reversal agent...

September 28, 2022

Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022

Markets

Cantor sees Hepion Pharma potentially emerging from under the radar

In a new research report, Cantor Fitzgerald writes that Hepion Pharmaceuticals (NASDAQ:HEPA) is a company that has largely flown under the radar despite already achieving some early proof-of-concept evidence and having...

September 21, 2022

Markets

WB ups Larimar to OP after Phase 2 clinical hold lifted

William Blair upgraded Larimar Therapeutics (NASDAQ:LRMR) to “outperform” after the FDA approved the company’s proposed Phase 2 study design for CTI-1601 in Friedreich’s ataxia (FA), enabling a return to clinical...

September 19, 2022

Markets

HCW starts Everest Medicines at buy; PT $30 HK

H.C. Wainwright launched coverage of Everest Medicines (HKSE:1952.HK) with a “buy” rating and price target of $30 HK. The stock closed at $10.38 HK on Sept. 8. Everest Medicines is an integrated biopharmaceutical...

September 9, 2022

Markets

BTIG starts Annexon at buy; PT $15

BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...

September 9, 2022

Markets

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor Fitzgerald initiated coverage of Asensus Surgical (NYSE American:ASXC) with an “overweight” rating and price target of $1.50. The stock closed at 53 cents on Sept. 7. Asensus is a robotic-assisted surgery company...

September 8, 2022

Markets

Cantor starts Actinium Pharma at OW; PT $20

Cantor Fitzgerald launched coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with an “outperform” rating and $20 price target. The stock closed at $7.51 on Sept. 7. Actinium is a clinical-stage biopharmaceutical...

September 8, 2022

Markets

Piper starts Miromatrix Medical at OW; PT $8

Piper Sandler launched coverage of Miromatrix Medical (NASDAQ:MIRO) with an “overweight” rating and $8 price target. The stock closed at $2.92 on Aug. 30. Miromatrix has developed a proprietary perfusion technology...

August 31, 2022

Markets

Dawson James starts Smart for Life at buy; PT $8

Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...

August 29, 2022

Category - Markets

Stifel cuts PhaseBio to hold on bentracimab ownership dispute

Maxim starts BioRestorative Therapies at buy; PT $6

Cantor sees Hepion Pharma potentially emerging from under the radar

WB ups Larimar to OP after Phase 2 clinical hold lifted

HCW starts Everest Medicines at buy; PT $30 HK

BTIG starts Annexon at buy; PT $15

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor starts Actinium Pharma at OW; PT $20

Piper starts Miromatrix Medical at OW; PT $8

Dawson James starts Smart for Life at buy; PT $8

General

More